Armando Santoro

TL;DR: VeriStrat® (V), a proteomic test using Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS), was used in the present study to classify baseline plasma samples from NExUS patients into V Good (VG) and V Poor (VP) categories to determine if V status was predictive of sorafenib + GC clinical activity.

TL;DR: For a CMV- patient, the use of aCMV+ donor did not appear to impair survival after haplo-SCT with PT-Cy, but outcome of CMV+ patients is worse thanCMV- patients, without significant differences according to donor CMV serostatus.

TL;DR: Hematology, Oncology, Institute of Southern Switzerland and Institute of oncology Research, Bellinzona, Switzerland; Hematologists, Instituto Português de Oncologia de Lisboa, Lisbona, Portugal; Humanitas Clinical and Research Center, Humanitas Cancer Center, Rozzano, Italy; Hem atology, Ospedale degli Infermi, Rimini, Italy.

TL;DR: It is found that unmanipulated haploidentical transplant (HaploSCT) with high dose post-transplant cyclophosphamide (PT-Cy) was a potential effective strategy with a 3-year PFS and OS of 63 and 77%, respectively.

TL;DR: This study reported a high level of activity in metastatic and locally advanced disease by using a weekly intensive chemotherapy with cisplatin, epidoxorubicin, 5fluorouracil and lederfolin (wPELF) in adjuvant setting.